Abstract

The present invention relates to a method for preparation of 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one, and intermediate compounds thereof.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Abstract

The present invention relates to a phosphate salt of 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d] pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one, a crystalline form thereof, and a method for preparing same. The phosphate salt and the crystalline form have low hygroscopicity and improved stability and solubility, compared to free bases, and thus are suitable for pharmaceutical use. Also, the method for preparing the phosphate or crystalline form, of the present invention, has the advantages of enabling mass production and improving the safety of preparation processes by using a safe material compared to reactants used in conventional preparation methods.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Abstract

The present invention relates to a tartrate salt of 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one, a crystalline form thereof, and a method for preparing same. The tartrate salt and the crystalline form have lower hygroscopicity and improved stability and solubility compared to a free base, and thus are suitable for pharmaceutical use. In addition, the method for preparing the tartrate salt or crystalline form of the present invention has the advantage of enabling mass production and improving the safety of the preparation process by using safer substances than reactants used in conventional preparation methods.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Abstract

The present disclosure relates to a novel heterocyclic compound represented by the Chemical Formula 1 and a pharmaceutical composition comprising the same, and the compound according to the present disclosure can be usefully used for the prevention or treatment of cancer.

IPC Classes  ?

• C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention provides a pharmaceutical composition comprising a compound represented by Chemical Formula 1 described in the present specification, or a pharmaceutically acceptable salt thereof, and a chemotherapeutic agent. The pharmaceutical composition can be usefully used for preventing or treating triple-negative breast cancer.

IPC Classes  ?

• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure relates to a compound represented by Chemical Formula 1 in the present specification, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same can be used favorably for preventing or treating cancer or tumors.

IPC Classes  ?

• A61K 31/69 - Boron compounds
• C07F 5/02 - Boron compounds

Abstract

The present invention relates to a pharmaceutical composition comprising enavogliflozin as an active ingredient for preventing or treating obesity in canine animals. The composition can be advantageously used for preventing or treating obesity in canine animals because it reduces the body condition score, body weight, fat thickness, body fat percentage, chest circumference, and waist circumference of obesity dogs, and has an excellent improvement effect on serological indicators.

IPC Classes  ?

• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61P 3/04 - AnorexiantsAntiobesity agents

Abstract

The present invention relates to a compound represented by chemical formula 1 of the present specification or a pharmaceutically acceptable salt thereof. The compound according to the present invention can be effectively used for preventing or treating cancer or tumors.

IPC Classes  ?

• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
• A61P 35/00 - Antineoplastic agents
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 487/04 - Ortho-condensed systems

Abstract

The present invention relates to a method for producing an intermediate useful for the synthesis of an SGLT inhibitor. According to the present invention, a compound of Chemical Formula 9, which is an important intermediate for a compound of Chemical Formula 1 as an SGTL inhibitor, may be obtained with high yield and high quality. A method for producing the SGLT inhibitor according to the present invention enables production without special facilities such as an ozone generator and thus is also much more economical.

IPC Classes  ?

• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• C07D 307/78 - Benzo [b] furansHydrogenated benzo [b] furans

Abstract

The present invention relates to a pharmaceutical composition comprising enavogliflozin as an active ingredient for preventing or treating obesity in canine animals. The composition can be advantageously used for preventing or treating obesity in canine animals because it reduces the body condition score, body weight, fat thickness, body fat percentage, chest circumference, and waist circumference of obesity dogs, and has an excellent improvement effect on serological indicators.

IPC Classes  ?

• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61P 3/04 - AnorexiantsAntiobesity agents

Abstract

The present invention relates to a method for producing an intermediate useful for the synthesis of an SGLT inhibitor. According to the present invention, a compound of Chemical Formula 9, which is an important intermediate for a compound of Chemical Formula 1 as an SGTL inhibitor, may be obtained with high yield and high quality. A method for producing the SGLT inhibitor according to the present invention enables production without special facilities such as an ozone generator and thus is also much more economical.

IPC Classes  ?

• C07D 307/80 - Radicals substituted by oxygen atoms
• C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

The present disclosure relates to a formulation for oral administration comprising 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl) sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine exhibiting improved dissolution properties.

IPC Classes  ?

• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/28 - DrageesCoated pills or tablets

Abstract

A compound represented by Chemical Formula 1 or 2 of the present invention, or a pharmaceutically acceptable salt thereof can be used favorably for preventing or treating cancer or tumors.

IPC Classes  ?

• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 31/415 - 1,2-Diazoles
• A61K 31/4164 - 1,3-Diazoles
• A61K 31/426 - 1,3-Thiazoles
• A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61P 35/00 - Antineoplastic agents
• C07C 237/20 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
• C07D 213/16 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
• C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
• C07D 213/82 - AmidesImides in position 3
• C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 233/64 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
• C07D 277/28 - Radicals substituted by nitrogen atoms
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

A compound represented by Chemical Formula 1 or 2 of the present invention, or a pharmaceutically acceptable salt thereof can be used favorably for preventing or treating cancer or tumors.

IPC Classes  ?

• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 31/4164 - 1,3-Diazoles
• A61K 31/426 - 1,3-Thiazoles
• A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• C07C 237/20 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
• C07D 213/16 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring

Abstract

The present disclosure provides novel (2R,3S)-2-(3-(4,5-dichloro-1H-benzo[d]imidazol-1 -yl)propyl)piperidin-3-ol monohydrochloride, (2R,3S)-2-(3-(4,5-dichloro-1H-benzo[d]imidazol-1 -yl)propyl)piperidin-3-ol oxalate, (2R,3S)-2-(3-(4,5-dichloro-1H-benzo[d]imidazol-1 -yl)propyl)piperidin-3-ol maleate, (2R,3S)-2-(3-(4,5-dichloro-1H-benzo[d]imidazol-1 -yl)propyl)piperidin-3-ol palmitate, and crystalline form of (2R,3S)-2-(3-(4,5-dichloro-1H-benzo[d]imidazol-1-yl)propyl)piperidin-3-ol monohydrochloride. These novel acid addition salts and crystalline forms have low hygroscopicity and excellent severe stability under high temperature and high humidity conditions, and thus can be used pharmaceutically.

IPC Classes  ?

• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone

Abstract

The present invention relates to a compound represented by chemical formula 1 or a pharmaceutically acceptable salt thereof. The compound according to the present invention can be effectively used for preventing or treating cancer or tumors.

IPC Classes  ?

• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
• A61P 35/00 - Antineoplastic agents
• C07D 487/04 - Ortho-condensed systems
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

The present invention relates to a method for preparing (2R, 3S)-2-(benzo[d]imidazolylpropyl)piperidin-3-ol derivatives, and the preparation method according to the present invention has the advantage that the compound can be prepared in high yield even with a shortened process.

IPC Classes  ?

• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C12P 17/12 - Nitrogen as only ring hetero atom containing a six-membered hetero ring

Goods & Services

Pharmaceutical preparations for treating diabetes; pharmaceutical agents affecting metabolism; vitamin preparations; anti-inflammatory preparations; drugs for medical purposes; pharmaceuticals; veterinary preparations; medicines for human purposes; therapeutic drugs and agents; anti-diabetic pharmaceuticals; hypoglycemic agents; pharmaceutical preparations for the treatment of kidney diseases; pharmaceutical preparations for preventing and treating obesity; chemico-pharmaceutical preparations; vaccines; cardiovascular pharmaceuticals; ferments for pharmaceutical purposes; nutritional supplements; diagnostic preparations for medical purposes; cardiovascular pharmaceutical preparations.

Abstract

The present disclosure relates to a novel heterocyclic compound represented by the Chemical Formula 1 and a pharmaceutical composition comprising the same, and the compound according to the present disclosure can be usefully used for the prevention or treatment of cancer.

IPC Classes  ?

• C07D 223/16 - BenzazepinesHydrogenated benzazepines
• C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention provides an appropriate dosage regimen for each indication of a fexuprazan injection composition and thereby enable obtaining an optimal preventive or therapeutic effect therefrom.

IPC Classes  ?

• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Abstract

The present invention relates to an antiviral composition against influenza virus and a pharmaceutical composition for preventing or treating influenza virus infection, each comprising xanthan gum or fucoidan as an active ingredient, and a method for preventing or treating influenza virus infection using same.

IPC Classes  ?

• A61K 31/723 - Xanthans
• A61K 31/737 - Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

The present invention relates to: a solid dispersion comprising a poorly soluble donepezil salt or hydrate or solvate thereof that has an acetylcholine esterase inhibitory effect; a method for preparing same; and a pharmaceutical composition for parenteral administration, comprising the solid dispersion and having an improved drug content of donepezil. The solid dispersion comprising a poorly soluble donepezil salt and a biodegradable release-controlling polymer, according to the present invention, is suitable for preparing a long-acting parenteral pharmaceutical composition having an improved drug content of donepezil. The parenteral pharmaceutical composition according to the present invention can reduce a dose as the drug content of donepezil increases, and can significantly increase the therapeutic effect and medication compliance by maintaining the blood concentration of the drug for a long period of time. The solid dispersion comprising a poorly soluble donepezil salt and a biodegradable release-controlling polymer, according to the present invention, has a relatively simple preparation process, does not cause initial burst problems, and does not use an organic solvent, thus significantly increasing in vivo safety.

IPC Classes  ?

• A61K 9/14 - Particulate form, e.g. powders
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61K 9/10 - DispersionsEmulsions
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

112233 are as defined in the specification.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 35/00 - Antineoplastic agents

Abstract

122, and m are the same as defined in the specification.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
• A61K 31/538 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
• A61P 35/00 - Antineoplastic agents

Abstract

The pharmaceutical composition according to the present invention can be usefully used for the prevention or treatment of systemic fibrosis.

IPC Classes  ?

• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 17/00 - Drugs for dermatological disorders

Abstract

The present invention relates to a manufacturing method for 4-methoxypyrrole derivatives, and according to an embodiment of the present invention, the number of days for manufacturing is reduced by half, leading to improvements in process efficiency and yield and a useful advantage for the industrial mass production of 4-methoxypyrrole derivatives.

IPC Classes  ?

• C07D 207/48 - Sulfur atoms
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Abstract

The present disclosure relates to a medicine container containing a liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine, or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61K 9/08 - Solutions
• A61J 1/05 - Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids
• A61J 1/14 - Containers specially adapted for medical or pharmaceutical purposes DetailsAccessories therefor
• A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/40 - CyclodextrinsDerivatives thereof

Abstract

The present disclosure relates to a formulation for injection comprising 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine.

IPC Classes  ?

• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/40 - CyclodextrinsDerivatives thereof

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating diabetes mellitus in an animal of the family Canidae, including enavogliflozin as an active ingredient. The pharmaceutical composition, of the present invention, including enavogliflozin as an active ingredient exhibits an excellent blood glucose level control effect and thus can be effectively used for treating diabetes mellitus in an animal of the family Canidae.

IPC Classes  ?

• A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
• A61K 38/28 - Insulins
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The present disclosure relates to a pharmaceutical composition that can be usefully used for the prevention or treatment of fibrosis. According to the present invention, there is a feature that the preventive or therapeutic effect of fibrosis can be further enhanced by using the first component and the second component in combination.

IPC Classes  ?

• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/28 - DrageesCoated pills or tablets
• A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

The pharmaceutical composition according to the present invention is used at specific therapeutic regimen and dosage, and can be usefully used for the prevention or treatment of fibrosis.

IPC Classes  ?

• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

The present invention relates to a pharmaceutical composition comprising enavogliflozin and metformin. The pharmaceutical composition, according to the present invention, makes it possible to implement an excellent preparation that provides the same level of medicinal efficacy as the combination therapy of a single tablet of metformin and a single tablet of enavogliflozin, despite a large content difference between metformin and enavogliflozin.

IPC Classes  ?

• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/24 - Layered or laminated unitary dosage forms
• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring

Abstract

The present invention relates to a device for nasal administration of a drug and comprises a container part and a nozzle part. The container part accommodates powdered medicine and has a guiding part which has a guiding hole provided at the upper end to guide the powdered medicine toward the guiding hole. The nozzle part is coupled to the upper portion of the container part and is inserted into the nasal cavity of a patient to spray the powdered medicine. In addition, the nozzle part comprises: a measuring part, which is in communication with the guiding part to measure a predetermined amount of the powdered medicine that has been guided thereto through the guiding part; and a flow tube, which is in communication with the measuring part and through which the powdered medicine measured by the measuring part moves along with internal air and is discharged when the container part is pressed. The central axis of the measuring part is arranged to be spaced apart from the central axis of the flow tube.

IPC Classes  ?

• A61M 15/08 - Inhaling devices inserted into the nose
• A61M 11/00 - Sprayers or atomisers specially adapted for therapeutic purposes

Abstract

An emulsion homogenization apparatus, according to an embodiment of the present invention, comprises: a stirring container; a stirring unit provided with a stirring shaft and stirring blades and installed in the stirring container so as to be able to rotate; and a medicinal fluid injection part having a discharge port through which a main ingredient aqueous solution containing a drug is discharged in the form of droplets, the discharge port being installed in the stirring container, between the bottom surface of the stirring container and the stirring blades, so as to face the stirring blades.

IPC Classes  ?

• B01F 23/43 - Mixing liquids with liquidsEmulsifying using driven stirrers
• B01F 23/41 - Emulsifying
• B01F 27/2122 - Hollow shafts
• B01F 27/91 - Mixers with rotary stirring devices in fixed receptaclesKneaders with stirrers rotating about a substantially vertical axis with propellers
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 38/09 - Luteinising hormone-releasing hormone [LHRH]Related peptides
• B01F 101/22 - Mixing of ingredients for pharmaceutical or medical compositions

Abstract

The present invention relates to: a composition with improved bioavailability of niclosamide, including niclosamide or a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof, and an extracellular matrix lyase; a pharmaceutical composition including the composition; and a method for preparing the composition.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61P 33/10 - Anthelmintics

Abstract

The present invention relates to a formulation capable of inhibiting the early release of a specific PRS inhibitor and has the effect of preventing the side effects of nausea or vomiting, which may occur when too much of an active ingredient is absorbed at an early stage.

IPC Classes  ?

• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/28 - DrageesCoated pills or tablets
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The present invention relates to a pretreatment method for isolating a TGF-β3 protein from E. coli and purifying same with high efficiency and high purity, and a TGF-β3 protein purification method comprising the pretreatment method. The pretreatment method and the purification method comprising same, according to the present invention, use E. coli, and thus are expected to have simpler processes and higher productivity than animal cell culture methods such that highly-pure TGF-β3 protein can be isolated from E. coli and purified with high efficiency and and high purity.

IPC Classes  ?

• C07K 14/495 - Transforming growth factor [TGF]
• C07K 1/02 - General processes for the preparation of peptides in solution
• C07K 1/20 - Partition-, reverse-phase or hydrophobic interaction chromatography
• C07K 1/18 - Ion-exchange chromatography
• C07K 1/34 - ExtractionSeparationPurification by filtration, ultrafiltration or reverse osmosis

Abstract

The present invention provides a pharmaceutical composition advantageously useful for preventing or treating nephritis.

IPC Classes  ?

• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention relates to a pharmaceutical composition comprising enavogliflozin as an active ingredient for the prevention or treatment of diabetes and/or renal diseases in patients who have or are at risk of diabetes and/or renal diseases.

IPC Classes  ?

• A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating cardiovascular aging diseases, comprising enavogliflozin as an active ingredient. Enavogliflozin of the present invention exhibits excellent effects in the prevention and treatment of endothelial dysfunction caused by vascular endothelial senescence, and cardiovascular aging diseases related thereto.

IPC Classes  ?

• A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
• A61P 9/00 - Drugs for disorders of the cardiovascular system

Abstract

infinf) and thus can be usefully employed for various indications and/or in the development of formulations that require prolonged efficacy.

IPC Classes  ?

• C07D 407/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
• A61K 9/14 - Particulate form, e.g. powders
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The present invention relates to a novel crystalline form of enavogliflozin, and a preparation method therefor. The novel crystalline form of enavogliflozin, according to the present invention, has thermodynamic stability and a hygroscopic property that are superior to those of a conventionally reported crystalline form of enavogliflozin, and thus has excellent long-term storage and pharmaceutical stability. In addition, the time to reach Cmax is shorter than that of the conventionally reported crystalline form of enavogliflozin such that drug effects can be rapidly exhibited, and thus the present invention can be effectively used.

IPC Classes  ?

• C07D 407/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The present invention relates to a novel genomic safe harbor (GSH), a method for expressing an exogenous gene using same, and cells introduced with an exogenous gene by the same method. The method for expressing an exogenous gene using the novel genomic safe harbor according to the present invention allows the safe introduction and long-term stable expression of an exogenous gene without disrupting the transcription of adjacent genes, thereby enabling the safe expression of various exogenous genes within cells without safety concerns.

IPC Classes  ?

• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 9/22 - Ribonucleases

Abstract

The present invention relates to a pharmaceutical composition comprising a metabolite of enavogliflozin, and a use thereof. An enavogliflozin M1 metabolite of chemical formula 1 is a SGLT1/SGLT2 dual inhibitor and exhibits a different pharmacological mechanism from enavogliflozin which is a SGLT2 selective inhibitor. A pharmaceutical composition comprising, as an active ingredient, the enavogliflozin M1 metabolite that is a SGLT1/SGLT2 dual inhibitor can be useful in the prevention or treatment of diabetes or heart failure.

IPC Classes  ?

• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Goods & Services

Medicines for veterinary purposes; nutritional supplements for animal foodstuffs; protein supplements for animals; preparations of trace elements for animal use; veterinary vaccines; vitamins for animals; insecticidal animal shampoos; feeding stimulants for animals; dietary supplements for animals; veterinary preparations; skin treatment [medicated] for animals; antibiotic food supplements for animals; anaesthetics; feed supplements for veterinary purposes; biological preparations for veterinary purposes; pharmaceutical preparations for the treatment of worms in pets; diapers for pets; medicated animal feed; medicated supplements for foodstuffs for animals; pharmaceuticals.

Goods & Services

Medicines for veterinary purposes; nutritional supplements for animal foodstuffs; protein supplements for animals; preparations of trace elements for animal use; veterinary vaccines; vitamins for animals; insecticidal animal shampoos; feeding stimulants for animals; dietary supplements for animals; veterinary preparations; skin treatment [medicated] for animals; antibiotic food supplements for animals; anaesthetics; feed supplements for veterinary purposes; biological preparations for veterinary purposes; pharmaceutical preparations for the treatment of worms in pets; diapers for pets; medicated animal feed; medicated supplements for foodstuffs for animals; pharmaceuticals.

Goods & Services

Medicines for veterinary purposes; nutritional supplements for animal foodstuffs; protein supplements for animals; preparations of trace elements for animal use; veterinary vaccines; vitamins for animals; insecticidal animal shampoos; feeding stimulants for animals; dietary supplements for animals; veterinary preparations; skin treatment [medicated] for animals; antibiotic food supplements for animals; anaesthetics; feed supplements for veterinary purposes; biological preparations for veterinary purposes; pharmaceutical preparations for the treatment of worms in pets; diapers for pets; medicated animal feed; medicated supplements for foodstuffs for animals; pharmaceuticals.

Abstract

The present invention relates to a compound represented by chemical formula 1 of the present specification, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising same can be effectively used in the prevention or treatment of cancer or tumors.

IPC Classes  ?

• C07F 5/02 - Boron compounds
• A61K 31/69 - Boron compounds
• A61P 35/00 - Antineoplastic agents

Goods & Services

Medicines for veterinary purposes, namely for treatment of metabolic diseases; animal feed additives for use as nutritional supplements; protein supplements for animals; preparations of trace elements for animal use, namely, vitamin and mineral supplements for animals; veterinary vaccines; vitamins for animals; insecticidal animal shampoos; feeding stimulants for animals; dietary supplements for animals; veterinary preparations for treatment of metabolic diseases; pharmaceuticals for treating diabetes for veterinary purposes; medicated veterinary preparations for treating skin disorders; antibiotic food supplements for animals; anaesthetics; animal feed supplements for veterinary purposes; biological preparations for veterinary purposes, namely, biological reagents for veterinary purposes; biological preparations for veterinary purposes, namely, biological tissue cultures for veterinary purposes; pharmaceutical preparations for the treatment of worms in pets; diapers for pets; medicated animal feed; medicated supplements for foodstuffs for animals; pharmaceuticals for preventing diabetes for veterinary purposes; pharmaceuticals for preventing metabolic diseases for veterinary purposes; pharmaceuticals for treating metabolic diseases for veterinary purposes

Goods & Services

Medicines for veterinary purposes, namely, for treatment of metabolic diseases; animal feed additives for use as nutritional supplements; protein supplements for animals; preparations of trace elements for animal use, namely, vitamin and mineral supplements for animals; veterinary vaccines; vitamins for animals; insecticidal animal shampoos; feeding stimulants for animals; dietary supplements for animals; veterinary preparations for treatment of metabolic diseases; pharmaceuticals for treating diabetes for veterinary purposes; medicated veterinary preparations for treating skin disorders; antibiotic food supplements for animals; anaesthetics; animal feed supplements for veterinary purposes; biological preparations for veterinary purposes, namely, biological reagents for veterinary purposes; biological preparations for veterinary purposes, namely, biological tissue cultures for veterinary purposes; pharmaceutical preparations for the treatment of worms in pets; diapers for pets; medicated animal feed; medicated supplements for foodstuffs for animals; pharmaceuticals for preventing diabetes for veterinary purposes; pharmaceuticals for preventing metabolic diseases for veterinary purposes; pharmaceuticals for treating metabolic diseases for veterinary purposes

Goods & Services

Medicines for veterinary purposes, namely for treatment of metabolic diseases; animal feed additives for use as nutritional supplements; protein supplements for animals; preparations of trace elements for animal use, namely, vitamin and mineral supplements for animals; veterinary vaccines; vitamins for animals; insecticidal animal shampoos; feeding stimulants for animals; dietary supplements for animals; veterinary preparations for treatment of metabolic diseases; medicated veterinary preparations for treating skin disorders; antibiotic food supplements for animals; anaesthetics; animal feed supplements for veterinary purposes; biological preparations for veterinary purposes, namely, biological reagents for veterinary purposes; biological preparations for veterinary purposes, namely, biological tissue cultures for veterinary purposes; pharmaceutical preparations for the treatment of worms in pets; diapers for pets; medicated animal feed; medicated supplements for foodstuffs for animals; pharmaceuticals for preventing diabetes for veterinary purposes; pharmaceuticals for preventing metabolic diseases for veterinary purposes; pharmaceuticals for treating metabolic diseases for veterinary purposes

Abstract

The present application relates to compounds of formula (I) or (Ia) (e.g., fexuprazan), for treating pathological hypersecretory conditions, such as a condition comprising gastric acid hypersecretion (e.g., Zollinger-Ellison syndrome, idiopathic gastric acid hypersecretion, and/or hypergastrinemia).

IPC Classes  ?

• A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Abstract

A method for preparing compound 1 and compound 2 having a structure as shown below, the method includes the following steps: A method for preparing compound 1 and compound 2 having a structure as shown below, the method includes the following steps: 1) subjecting 2,3-dihydrobenzofuran-7-amine as a raw material to a selective-dibromination with a brominating reagent to obtain 4,6-dibromo-2,3-dihydrobenzofuran-7-amine; 2) subjecting 4,6-dibromo-2,3-dihydrobenzofuran-7-amine obtained in the step 1) to Sandmeyer reaction for chlorination to obtain 4,6-dibromo-7-chloro-2,3-dihydrobenzofuran; 3-1) selectively debrominating from 4,6-dibromo-7-chloro-2,3-dihydrobenzofuran obtained in the step 2) using a strong base, and then adding a formylation reagent to obtain compound 1; 3-2) selectively debrominating from 4,6-dibromo-7-chloro-2,3-dihydrobenzofuran obtained in the step 2) using a strong base, and then reacting with 4-cyclopropyl benzaldehyde to obtain compound 2.

IPC Classes  ?

• C07D 307/79 - Benzo [b] furansHydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring

Abstract

A single dosage form of pharmaceutical composition for treatment of hypertension and hyperlipidemia is provided. Stability and uniform dissolution rates of drugs may be ensured by mixing compositions containing desired drugs and formulating the mixture into a single compartment form, whereby a manufacturing process becomes simple while reducing processing costs. Further, a formulation having biological equivalence to conventional single formulations may be obtained.

IPC Classes  ?

• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/28 - DrageesCoated pills or tablets
• A61K 31/4422 - 1,4-Dihydropyridines, e.g. nifedipine, nicardipine

Goods & Services

Pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating metabolic disorders; pharmaceutical agents affecting metabolism; vitamin preparations; anti-inflammatory preparations; drugs for medical purposes; pharmaceuticals; veterinary preparations; medicines for human purposes; therapeutic drugs and agents; antidiabetic preparations; anti-diabetic pharmaceuticals; hypoglycemic agents; pharmaceutical preparations for the treatment of kidney diseases; pharmaceutical preparations for preventing and treating obesity; pharmaceutical preparations for slimming purposes; pharmaceutical preparations for long-term maintenance of weight loss; pharmaceutical preparations for the treatment of chronic heart failure; pharmaceutical preparations for the treatment of heart failure; cardiovascular pharmaceuticals.

Abstract

The present invention relates to a pharmaceutical composition comprising enavogliflozin as an active ingredient for preventing or treating obesity in canine animals. The composition can be advantageously used for preventing or treating obesity in canine animals because it reduces the body condition score, body weight, fat thickness, body fat percentage, chest circumference, and waist circumference of obese dogs, and has an excellent improvement effect on serological indicators.

IPC Classes  ?

• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61P 3/04 - AnorexiantsAntiobesity agents

Abstract

The present invention relates to a method for producing an intermediate useful for the synthesis of an SGLT inhibitor. According to the present invention, a compound of chemical formula 9, which is an important intermediate for a compound of chemical formula 1 as an SGTL inhibitor, may be obtained with high yield and high quality. A method for producing the SGLT inhibitor according to the present invention enables production without special facilities such as an ozone generator and thus is also much more economical.

IPC Classes  ?

• C07D 307/78 - Benzo [b] furansHydrogenated benzo [b] furans
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin

Abstract

A compound represented by Formula 1 or 2 of the present invention, or a pharmaceutically acceptable salt thereof can be useful in the prevention or treatment of cancer or tumors.

IPC Classes  ?

• C07D 213/16 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/426 - 1,3-Thiazoles
• A61K 31/4164 - 1,3-Diazoles
• A61P 35/00 - Antineoplastic agents
• C07C 237/20 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings

Abstract

The present invention relates to a compound represented by chemical formula 1 in the present specification, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising a chemotherapeutic agent, wherein the pharmaceutical composition can be effectively used in the prevention or treatment of triple-negative breast cancer.

IPC Classes  ?

• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

The objective of the present invention is to provide an appropriate dosage regimen for each indication of a fexuprazan injection composition and thereby enable obtaining an optimal preventive or therapeutic effect therefrom.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Abstract

The present invention provides novel monohydrochloride of (2R, 3S)-2-(3-(4,5-dichloro-1H-benzo[d]imidazol-1-yl)propyl)piperidin-3-ol, oxalate of (2R, 3S)-2-(3-(4,5-dichloro-1H-benzo[d]imidazol-1-yl)propyl)piperidin-3-ol, maleate of (2R, 3S)-2-(3-(4,5-dichloro-1H-benzo[d]imidazol-1-yl)propyl)piperidin-3-ol, palmitate of (2R, 3S)-2-(3-(4,5-dichloro-1H-benzo[d]imidazol-1-yl)propyl)piperidin-3-ol, and crystalline forms of monohydrochloride of (2R, 3S)-2-(3-(4,5-dichloro-1H-benzo[d]imidazol-1-yl)propyl)piperidin-3-ol. These novel acid addition salts and crystalline forms have low hygroscopicity and excellent stability under harsh conditions of high temperature and high humidity, and thus can be pharmaceutically used.

IPC Classes  ?

• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61P 35/00 - Antineoplastic agents
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The objective of the present invention is to provide an appropriate dosage regimen for each indication of a fexuprazan injection composition and thereby enable obtaining an optimal preventive or therapeutic effect therefrom.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Abstract

The present invention provides novel monohydrochloride of (2R, 3S)-2-(3-(4,5-dichloro-1H-benzo[d]imidazol-1-yl)propyl)piperidin-3-ol, oxalate of (2R, 3S)-2-(3-(4,5-dichloro-1H-benzo[d]imidazol-1-yl)propyl)piperidin-3-ol, maleate of (2R, 3S)-2-(3-(4,5-dichloro-1H-benzo[d]imidazol-1-yl)propyl)piperidin-3-ol, palmitate of (2R, 3S)-2-(3-(4,5-dichloro-1H-benzo[d]imidazol-1-yl)propyl)piperidin-3-ol, and crystalline forms of monohydrochloride of (2R, 3S)-2-(3-(4,5-dichloro-1H-benzo[d]imidazol-1-yl)propyl)piperidin-3-ol. These novel acid addition salts and crystalline forms have low hygroscopicity and excellent stability under harsh conditions of high temperature and high humidity, and thus can be pharmaceutically used.

IPC Classes  ?

• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

The present invention relates to a method for preparation of (2R, 3S)-2-(benzo[d]imidazolylpropyl)piperidin-3-ol derivatives. The preparation method according to the present invention has the advantage of preparing the compound in a high yield even by simplified processes.

IPC Classes  ?

• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 211/42 - Oxygen atoms attached in position 3 or 5

Goods & Services

Pharmaceutical preparations for health care; nutritional supplements for animal foodstuffs; animal repellents; vitamins for animals; dietary supplements for animals; veterinary preparations; antibiotic food supplements for animals; pharmaceutical products for skin care for animals; preparations of trace elements for human and animal use; lotions for veterinary purposes; disinfectants for veterinary use; dietetic food adapted for veterinary use; veterinary preparations and substances; probiotic bacterial formulations for veterinary use; diapers for pets; medicated animal feed; dietetic animal foodstuffs for medical purposes; adhesive patches for medical purposes; ethical medicinal preparations; nutraceutical preparations for therapeutic or medical purposes. Flavorings for animal feed; livestock fattening preparations; animal foodstuffs; yeast for animal consumption; live fish [not for food]; fodder; live insects; live animals; algae, unprocessed, for human or animal consumption; fresh fruits and vegetables; sand for pet toilets; snacks for pets; litter for domestic animals; chewing gum for pets; pet food; powdered milk for pets; beverages for pets; pet treats, edible; pet birds.

Abstract

The present invention provides a novel crystalline form I of hydrochloride, a crystalline form II of hydrochloride, a crystalline form of succinate, a crystalline form of tartrate, a crystalline form I of fumarate and a crystalline form II of fumarate of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine. The above-described novel crystalline forms have high solubility in water and excellent stability under moisture-proof conditions and high-humidity exposure conditions, and thus can be pharmaceutically used.

IPC Classes  ?

• C07D 207/48 - Sulfur atoms
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

Abstract

The present invention relates to a pharmaceutical composition comprising enavogliflozin, which is a selective inhibitor of sodium-glucose cotransporter 2. A pharmaceutical composition comprising a compound of chemical formula 1 according to the present invention enables implementation of a formulation having excellent content uniformity, formulation uniformity, elution profile, and the like, despite comprising a low dose of a drug.

IPC Classes  ?

• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The present invention relates to a pharmaceutical composition comprising enavogliflozin, which is a selective inhibitor of sodium-glucose cotransporter 2. A pharmaceutical composition comprising a compound of chemical formula 1 according to the present invention enables implementation of a formulation having excellent content uniformity, formulation uniformity, elution profile, and the like, despite comprising a low dose of a drug.

IPC Classes  ?

• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The present disclosure relates to a method for preparing a heterocyclic amine derivative, and the preparation method according to the present disclosure has an advantage that a heterocyclic amine derivative having a reduced impurity content can be prepared in a high yield.

IPC Classes  ?

• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings

Abstract

An intermediate useful for the synthesis of an SGLT inhibitor and a method for preparing an SGLT inhibitor are provided. By employing an intermediate having Chemical Formula 5, the difficulty of purification with existing processes can be solved, the quality requirements for related substances can be achieved with only one purification step, and the quality control problem in each step can be solved by performing several steps in situ. A method for synthesizing a compound of Chemical Formula 1 by using a compound of Chemical Formula 5 enables purification in an earlier step, thereby solving the problems of existing synthesis processes, in which the quality requirements for related substances were difficult to control step-by-step due to a continuous process, thereby minimizing the amount of related substances in the final product. In addition, the yield of a diphenylmethane derivative according to Chemical Formula 1 is increased.

IPC Classes  ?

• C07D 407/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 307/79 - Benzo [b] furansHydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring

Abstract

A pharmaceutical composition according to the present invention can be usefully used for the prevention or treatment of systemic sclerosis.

IPC Classes  ?

• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 17/00 - Drugs for dermatological disorders

Abstract

A pharmaceutical composition according to the present invention can be usefully used for the prevention or treatment of systemic sclerosis.

IPC Classes  ?

• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61P 17/00 - Drugs for dermatological disorders
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

The present invention relates to a method for preparation of mesenchymal stem cells from human pluripotent stem cells and, more particularly, to a method for preparation of mesenchymal stem cells, wherein mesenchymal stem cells differentiated from embryoid bodies of a certain size in a xeno-free and serum-free environment are prepared, whereby the mesenchymal stem cells exhibit increased safety and maintain their own characteristics for a long period of time. A method for preparation of mesenchymal stem cells from human pluripotent stem cells according to the present invention employs a feeder cell-free, xeno-free, and serum-free culture environment to solve the problem of contamination with a foreign animal-derived material and allow the preparation of highly safe mesenchymal stem cells. In addition, the method utilizes spheroidal embryoid bodies to form mature embryoid bodies uniform in shape and size, thereby improving the differentiation efficiency to mesenchymal stem cells and exhibiting an exceptional effect of stably maintaining mesenchymal stem cell characteristics even after a long-term subculture, such as 20 or more passages, through which human pluripotent stem cell-derived mesenchymal stem cells can be prepared in a large amount. Therefore, the invention is advantageous for commercializing cell therapeutic agents superb in safety and efficiency.

IPC Classes  ?

• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells

Abstract

The present invention relates to a pharmaceutical composition for prevention or treatment of coronavirus infections, comprising a delayed-release composition of niclosamide or a pharmaceutically acceptable salt thereof, and a method for preventing or treating coronavirus infections by using the same.

IPC Classes  ?

• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61P 31/12 - Antivirals

Abstract

The present invention relates to a compound represented by the following Chemical Formula 1, or a pharmaceutically acceptable salt thereof, and the compound according to the present invention can be usefully used for the prevention or treatment of diseases which are associated with kinase inhibitory actions: The present invention relates to a compound represented by the following Chemical Formula 1, or a pharmaceutically acceptable salt thereof, and the compound according to the present invention can be usefully used for the prevention or treatment of diseases which are associated with kinase inhibitory actions: in Chemical Formula 1, R1 to R3 are as defined in the present specification.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

Abstract

The present invention can be usefully used as a liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine, or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61K 31/724 - Cyclodextrins
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets

Abstract

The present invention relates to an injectable formulation comprising 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrole-3-yl)-N-methylmethanamine or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• A61K 47/02 - Inorganic compounds
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/40 - CyclodextrinsDerivatives thereof
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Abstract

The present invention relates to a medicine container containing a liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine, or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61J 1/05 - Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids
• A61J 1/06 - Ampoules or cartridges
• A61K 9/08 - Solutions
• A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• A61K 47/02 - Inorganic compounds
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/40 - CyclodextrinsDerivatives thereof
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Abstract

The present invention relates to an injectable formulation comprising 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrole-3-yl)-N-methylmethanamine or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/40 - CyclodextrinsDerivatives thereof
• A61K 47/02 - Inorganic compounds
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Abstract

The present invention relates to a medicine container containing a liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine, or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61K 9/08 - Solutions
• A61K 47/40 - CyclodextrinsDerivatives thereof
• A61K 47/02 - Inorganic compounds
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61J 1/05 - Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids
• A61J 1/06 - Ampoules or cartridges

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating diabetes mellitus in an animal of the family Canidae, including enavogliflozin as an active ingredient. The pharmaceutical composition, of the present invention, including enavogliflozin as an active ingredient exhibits an excellent blood glucose level control effect and thus can be effectively used for treating diabetes mellitus in an animal of the family Canidae.

IPC Classes  ?

• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating diabetes mellitus in an animal of the family Canidae, comprising enavogliflozin as an active ingredient. The pharmaceutical composition, of the present invention, comprising enavogliflozin as an active ingredient exhibits an excellent blood sugar level control effect and can be effectively used for treating diabetes mellitus in an animal of the family Canidae.

IPC Classes  ?

• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 38/28 - Insulins
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

A pharmaceutical composition according to the present invention is used in a specific therapeutic dosage regimen, and can be effectively used for the prevention or treatment of fibrosis.

IPC Classes  ?

• A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The present invention relates to a pharmaceutical composition that can be usefully used for the prevention or treatment of fibrosis. By using a first component and a second component together according to the present invention, the prevention or treatment effect on fibrosis can be further enhanced.

IPC Classes  ?

• A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

A pharmaceutical composition according to the present invention is used in a specific therapeutic dosage regimen, and can be effectively used for the prevention or treatment of fibrosis.

IPC Classes  ?

• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The present invention relates to a pharmaceutical composition that can be usefully used for the prevention or treatment of fibrosis. By using a first component and a second component together according to the present invention, the prevention or treatment effect on fibrosis can be further enhanced.

IPC Classes  ?

• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The present invention relates to a method for preparing intermediates of 4-methoxypyrrole derivatives. The preparation method according to the present invention has advantages that the production cost can be lowered by using inexpensive starting materials, a high-temperature reaction is not required as a whole, inexpensive and non-explosive reagents are used instead of (trimethylsilyl)diazomethane, and further an intermediate of 4-methoxypyrrole derivatives can be prepared as a whole at a high yield.

IPC Classes  ?

• C07D 207/36 - Oxygen or sulfur atoms

Abstract

A preparation for percutaneous absorption contains a drug-containing matrix layer having a single-layered structure, in which a high dose of donepezil or a pharmaceutically acceptable salt thereof is contained in an amount of 10 to 20 wt % with respect to the total weight of the drug-containing matrix layer, thereby reducing the size of a formulation. The single-layered structure of the preparation allows for easy preparation at a production site and reduced manufacturing costs compared to preparations for percutaneous absorption having multi-layered structures. In addition, despite the high dose of donepezil contained in the preparation, no crystallization of donepezil occurs even during long-term storage, and the preparation continuously exhibits high skin permeability for a long period of time. Above all, due to a high drug dose per unit area, the size of a formulation is reduced compared to that of conventional formulations, and thus patient medication compliance can be remarkably increased.

IPC Classes  ?

• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 9/70 - Web, sheet or filament bases
• A61K 9/00 - Medicinal preparations characterised by special physical form

Goods & Services

Pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating metabolic disorders; pharmaceutical agents affecting metabolism; vitamin preparations; anti-inflammatory preparations; drugs for medical purposes; pharmaceuticals; veterinary preparations; medicines for human purposes; therapeutic drugs and agents; antidiabetic preparations; anti-diabetic pharmaceuticals; hypoglycemic agents; pharmaceutical preparations for the treatment of kidney diseases; pharmaceutical preparations for preventing and treating obesity; pharmaceutical preparations for slimming purposes; pharmaceutical preparations for long-term maintenance of weight loss; pharmaceutical preparations for the treatment of chronic heart failure; pharmaceutical preparations for the treatment of heart failure; cardiovascular pharmaceuticals.

Abstract

The present invention relates to a formulation for oral administration, comprising 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine exhibiting an improved elution characteristic.

IPC Classes  ?

• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Abstract

The present invention relates to a pharmaceutical composition for intramuscular and/or subcutaneous administration of niclosamide, containing niclosamide or a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof, the composition exhibiting the effect of maintaining a high blood concentration for a long time, and being effectively usable in the prevention or treatment of virus-related diseases.

IPC Classes  ?

• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 9/10 - DispersionsEmulsions
• A61K 47/38 - CelluloseDerivatives thereof
• A61P 31/12 - Antivirals
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention provides a pharmaceutical composition of a single dosage form for treating hypertension and hyperlipidemia. According to the present invention, compartments comprising a drug are formulated in separate forms so as to solve problems related to the dissolution and absorption of the drug due to drug interaction, and a biologically equivalent preparation can be obtained when compared to conventional single preparation.

IPC Classes  ?

• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/24 - Layered or laminated unitary dosage forms
• A61K 9/28 - DrageesCoated pills or tablets
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 31/4422 - 1,4-Dihydropyridines, e.g. nifedipine, nicardipine

Abstract

The present invention relates to a composition comprising albumin-bound Slit3 LRRD2 for prevention or treatment of a muscle disease, and more particularly provides a fusion protein comprising albumin-bound Slit3 LRRD2, a nucleic acid molecule encoding the fusion protein, a recombinant vector comprising the nucleic acid molecule, a transformant comprising the recombinant vector, a method for preparing a fusion protein using the transformant, a composition comprising the fusion protein for prevention or treatment of a muscle disease, and a composition comprising the fusion protein for improving the in vivo half-life of LRRD2 of the Slit 3 protein.

IPC Classes  ?

• A61K 38/38 - Albumins
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The present invention relates to a composition comprising albumin-bound LRRD2 of the SLIT3 protein for prevention or treatment of bone-related diseases.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Goods & Services

Pharmaceutical agents affecting digestive organs; medicines for treating intestinal disorders; proton-pump inhibitors; medicines for the treatment of gastrointestinal diseases; medicines for human purposes; pharmaceutical preparations; ethical medicinal preparations.

Abstract

A method for preparing compound 1and compound 2 having a structure as shown below, the method comprises the following steps: 1) subjecting 2,3-dihydrobenzofuran-7-amine as a raw material to a selective -dibromination with a brominating reagent to obtain 4,6-dibromo-2,3-dihydrobenzofuran-7- amine; 2) subjecting 4,6-dibromo-2,3-dihydrobenzofuran-7-amine obtained in the step 1) to Sandmeyer reaction for chlorination to obtain 4,6-dibromo -7-chloro-2,3-dihydrobenzofuran; 3-1) selectively debrominating from 4,6-dibromo-7-chloro-2,3-dihydrobenzofuran obtained in the step 2) using a strong base, and then adding a formylation reagent to obtain compound 1; 3-2) selectively debrominating from 4,6-dibromo-7-chloro-2,3-dihydrobenzofuran obtained in the step 2) using a strong base, and then reacting with 4-cyclopropyl benzaldehyde to obtain compound 2.

IPC Classes  ?

• C07D 307/79 - Benzo [b] furansHydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring

Goods & Services

Preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations; dietary supplements for medical purposes; pharmaceuticals; lipid lowering agents; cholesterol absorption inhibitors.

Abstract

The present invention relates to a pharmaceutical composite formulation containing a composition comprising rosuvastatin or a salt thereof and ezetimibe or a salt thereof, wherein the pharmaceutical composition may further comprise olmesartan medoxomil and amlodipine or a salt thereof. According to the present invention, the composition containing drugs is mixed and formulated into a single form to minimize the problems related to the drug dissolution and absorption due to interaction between the drugs and to secure stability and uniform dissolution rates of drugs, whereby a biologically equivalent formulation can be obtained when compared to conventional single formulations.

IPC Classes  ?

• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/50 - Microcapsules
• A61K 9/28 - DrageesCoated pills or tablets
• A61K 9/24 - Layered or laminated unitary dosage forms
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
• A61K 31/4164 - 1,3-Diazoles
• A61K 31/4422 - 1,4-Dihydropyridines, e.g. nifedipine, nicardipine

Abstract

The present disclosure relates to a novel heterocyclic amine derivative represented by the following Chemical Formula 1 and a pharmaceutical composition comprising the same, and the compound according to the present disclosure can be usefully used for the prevention or treatment of autoimmune diseases or cancers. 2, L, Y, A and B are the same as defined in the specification.

IPC Classes  ?

• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 471/04 - Ortho-condensed systems
• A61K 31/4427 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems
• A61K 31/4523 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 487/04 - Ortho-condensed systems

Abstract

The present invention provides a pharmaceutical composition of a single dosage form for treating hypertension and hyperlipidemia. According to the present invention, a composition containing a drug is mixed and formulated in a single compartment form, and thus the stability and uniform dissolution rate of the drug are ensured, thereby simplifying the manufacturing process and allowing the process cost to be reduced, and allowing a bioequivalent formulation as compared to a conventional single formulation to be obtained.

IPC Classes  ?

• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/4164 - 1,3-Diazoles
• A61K 31/4422 - 1,4-Dihydropyridines, e.g. nifedipine, nicardipine
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61K 9/28 - DrageesCoated pills or tablets
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets